フィルター
4 件の結果が “9173” で取得されました
並べ替える:
アルファベット順（A-Z）
ベストセラー
huIL1RL1(IL33R)
製品ID :
C001632
系統:
C57BL/6NCya
状況:
説明:
The IL1RL1 gene, also known as ST2 or IL33R, encodes a member of the interleukin-1 receptor superfamily, specifically binding the cytokine IL-33, a key mediator of inflammation and immunity [1]. This gene produces two primary protein isoforms: transmembrane ST2L and soluble sST2. ST2L, the functional receptor, is expressed on immune cells, including mast cells, helper T cells, and eosinophils, as well as epithelial and endothelial cells [1]. Upon IL-33 binding, ST2L activation initiates NF-κB and MAPK inflammatory signaling cascades, leading to the release of cytokines and chemokines that drive type II inflammation, fibrosis, and tumor microenvironment modulation [1-4]. The IL-33/ST2 axis exhibits context-dependent functions in tumors, potentially promoting proliferation, metastasis, and angiogenesis, or conversely, activating anti-tumor immunity and suppressing tumor growth [2]. Polymorphisms in IL1RL1 have been associated with increased susceptibility to a range of diseases, including asthma, allergies, cardiovascular diseases, inflammatory bowel disease, and cancers [1-5]. Consequently, the IL-33/ST2 signaling pathway has emerged as a focus of intense research for therapeutic intervention in diverse pathologies, with IL1RL1 representing a potential target for the development of novel therapies for cancer, inflammatory, and immune-related diseases [1-5].
The huIL1RL1(IL33R) mouse is a humanized model constructed using gene editing technology, where the mouse IL1RL1 signal peptide and endogenous extracellular domain were replaced with the human IL1RL1 signal peptide and extracellular domain. The murine IL1RL1 transmembrane and cytoplasmic region were preserved. Homozygous huIL1RL1(IL33R) mice are viable and fertile. This model can be used for studying the pathological mechanisms and therapeutic approaches of cancer, inflammatory, and immune-related diseases, and for the development of IL1RL1-targeted drugs.
The IL1RL1 gene, also known as ST2 or IL33R, encodes a member of the interleukin-1 receptor superfamily, specifically binding the cytokine IL-33, a key mediator of inflammation and immunity [1]. This gene produces two primary protein isoforms: transmembrane ST2L and soluble sST2. ST2L, the functional receptor, is expressed on immune cells, including mast cells, helper T cells, and eosinophils, as well as epithelial and endothelial cells [1]. Upon IL-33 binding, ST2L activation initiates NF-κB and MAPK inflammatory signaling cascades, leading to the release of cytokines and chemokines that drive type II inflammation, fibrosis, and tumor microenvironment modulation [1-4]. The IL-33/ST2 axis exhibits context-dependent functions in tumors, potentially promoting proliferation, metastasis, and angiogenesis, or conversely, activating anti-tumor immunity and suppressing tumor growth [2]. Polymorphisms in IL1RL1 have been associated with increased susceptibility to a range of diseases, including asthma, allergies, cardiovascular diseases, inflammatory bowel disease, and cancers [1-5]. Consequently, the IL-33/ST2 signaling pathway has emerged as a focus of intense research for therapeutic intervention in diverse pathologies, with IL1RL1 representing a potential target for the development of novel therapies for cancer, inflammatory, and immune-related diseases [1-5].
The huIL1RL1(IL33R) mouse is a humanized model constructed using gene editing technology, where the mouse IL1RL1 signal peptide and endogenous extracellular domain were replaced with the human IL1RL1 signal peptide and extracellular domain. The murine IL1RL1 transmembrane and cytoplasmic region were preserved. Homozygous huIL1RL1(IL33R) mice are viable and fertile. This model can be used for studying the pathological mechanisms and therapeutic approaches of cancer, inflammatory, and immune-related diseases, and for the development of IL1RL1-targeted drugs.
huIL33/huIL33R
製品ID :
C002039
系統:
C57BL/6NCya
状況:
説明:
IL33 encodes interleukin-33 (IL-33), a member of the IL-1 cytokine family that functions as an important endogenous alarmin in the immune system [1]. IL-33 is mainly released by barrier tissue cells, such as epithelial cells and endothelial cells, under conditions including mechanical injury, pathogen infection, or oxidative stress. It binds to the IL1RL1/ST2 receptor complex expressed on the surface of various immune cells, including Th2 cells, mast cells, basophils, eosinophils, and group 2 innate lymphoid cells (ILC2s), thereby initiating downstream signaling cascades.
Interleukin-1 receptor-like protein 1 (IL1RL1), also known as ST2 or IL33R, is a member of the interleukin-1 receptor superfamily and serves as the specific receptor for IL-33, playing a critical role in inflammatory responses and immune regulation [2]. The IL1RL1 gene encodes two major protein isoforms: the transmembrane receptor ST2L and the soluble receptor sST2. Functional ST2L is primarily expressed on the surface of various cell types, including immune cells (such as mast cells, helper T cells, and eosinophils), epithelial cells, and endothelial cells [2]. Upon IL-33 stimulation, ST2L activation triggers downstream inflammatory signaling pathways, including NF-κB and MAPK pathways, promoting the release of cytokines and chemokines and participating in various biological processes, including type 2 inflammatory responses, fibrosis, and tumor microenvironment regulation [2-5]. The IL-33/IL1RL1 signaling pathway exhibits complex roles in cancer, potentially promoting tumor cell proliferation, metastasis, and angiogenesis, while also activating antitumor immunity and suppressing tumor growth [3].
The huIL33/huIL33R mouse is a dual-target humanized model obtained by crossing the huIL33 mouse (Catalog No.: C001722) with the huIL1RL1(IL33R) mouse (Catalog No.: C001632). This model is applicable for studying the pathogenesis of inflammatory diseases, including asthma, atopic dermatitis (AD), allergic rhinitis, and inflammatory bowel disease (IBD), as well as tumor-related diseases. It can also be used for the screening, development, and preclinical pharmacodynamic and safety evaluation of therapeutics targeting the IL-33/IL1RL1 pathway.
IL33 encodes interleukin-33 (IL-33), a member of the IL-1 cytokine family that functions as an important endogenous alarmin in the immune system [1]. IL-33 is mainly released by barrier tissue cells, such as epithelial cells and endothelial cells, under conditions including mechanical injury, pathogen infection, or oxidative stress. It binds to the IL1RL1/ST2 receptor complex expressed on the surface of various immune cells, including Th2 cells, mast cells, basophils, eosinophils, and group 2 innate lymphoid cells (ILC2s), thereby initiating downstream signaling cascades.
Interleukin-1 receptor-like protein 1 (IL1RL1), also known as ST2 or IL33R, is a member of the interleukin-1 receptor superfamily and serves as the specific receptor for IL-33, playing a critical role in inflammatory responses and immune regulation [2]. The IL1RL1 gene encodes two major protein isoforms: the transmembrane receptor ST2L and the soluble receptor sST2. Functional ST2L is primarily expressed on the surface of various cell types, including immune cells (such as mast cells, helper T cells, and eosinophils), epithelial cells, and endothelial cells [2]. Upon IL-33 stimulation, ST2L activation triggers downstream inflammatory signaling pathways, including NF-κB and MAPK pathways, promoting the release of cytokines and chemokines and participating in various biological processes, including type 2 inflammatory responses, fibrosis, and tumor microenvironment regulation [2-5]. The IL-33/IL1RL1 signaling pathway exhibits complex roles in cancer, potentially promoting tumor cell proliferation, metastasis, and angiogenesis, while also activating antitumor immunity and suppressing tumor growth [3].
The huIL33/huIL33R mouse is a dual-target humanized model obtained by crossing the huIL33 mouse (Catalog No.: C001722) with the huIL1RL1(IL33R) mouse (Catalog No.: C001632). This model is applicable for studying the pathogenesis of inflammatory diseases, including asthma, atopic dermatitis (AD), allergic rhinitis, and inflammatory bowel disease (IBD), as well as tumor-related diseases. It can also be used for the screening, development, and preclinical pharmacodynamic and safety evaluation of therapeutics targeting the IL-33/IL1RL1 pathway.
Fsd1l-KO
製品ID :
S-KO-09173
系統:
C57BL/6JCya
状況:
説明:
Fsd1l is located on chromosome 4 of mice. Nuclease Technology will be used to design sgRNA; Fsd1l knockout mice will be obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Fsd1l is located on chromosome 4 of mice. Nuclease Technology will be used to design sgRNA; Fsd1l knockout mice will be obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Or9k2-flox
製品ID :
S-CKO-09173
系統:
C57BL/6JCya
状況:
説明:
Or9k2 is located on chromosome 10 of mice. SgRNA and ssDNA will be designed using Nuclease Technology; Or9k2 conditional knockout mice will be obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm will be collected for cryopreservation.
Or9k2 is located on chromosome 10 of mice. SgRNA and ssDNA will be designed using Nuclease Technology; Or9k2 conditional knockout mice will be obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm will be collected for cryopreservation.
Items: 1 to 4 of 4
1